Vaginal dysbiosis and the risk of human papillomavirus and cervical cancer : systematic review and meta-analysis by Brusselaers, Nele et al.
Systematic Reviews ajog.orgVaginal dysbiosis and the risk of human
papillomavirus and cervical cancer: systematic
review and meta-analysis
Nele Brusselaers, MD, PhD; Sadeep Shrestha, PhD; Janneke van de Wijgert, MD, PhD;
Hans Verstraelen, MD, PhDervical cancer is considered aOBJECTIVE: The vaginal microbiota proposedly influence the association between hu-
man papillomavirus and cervical cancer. Our aim was to assess whether vaginal dys-
biosis affects human papilloma virus acquisition, persistence, and progression to related
cervical premalignancy.
DATA SORUCES: MEDLINE, Embase, CINAHL, Cochrane Library, and Web of Science
(inception until June 2018) were used for this study. The study protocol was registered at
PROSPERO (CRD42016035620).
STUDY ELIGIBILITY CRITERIA: This systematic review included all observational studies
reporting on incident human papilloma virus, persistent human papilloma virus, and/or
related cervical disease in women with or without vaginal dysbiosis prior to outcome
assessment.
STUDY APPRAISAL AND SYNTHESIS METHODS: We used random-effects models for
meta-analyses and report pooled relative risks with 95% confidence intervals. The risk
for incident and/or persistent human papilloma virus or related cervical disease based on
longitudinal results was determined.
RESULTS: Of 1645 unique articles, 15 mainly prospective cohort studies were included,
published between 2003 and 2017, including a total of 101,049 women. Vaginal
dysbiosis was associated with an increased risk of incident human papilloma virus
(overall relative risk, 1.33, 1.18e1.50, I2 ¼ 0%; among young women relative risk,C largely preventable disease because
of population-based screening and more
recent vaccination programs in high-
income countries, although it remains
the fourth most common cancer in
women worldwide.1,2 Of the estimated
527,600 new cases and 265,700 related
deaths annually, most occur towomen in
low- and middle-income countries.1,2
It is well established, both epidemi-
ologically and mechanistically, that
cervical cancer and its premalignant
precursor stages (cervical intra-
epithelial neoplasia [CIN]) are causally
related to oncogenic types of the hu-
man papillomavirus (HPV).3,4 How-
ever, from a public health perspective,
the association is less than
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1.43, 1.10e1.85, I2 ¼ 0%), human papilloma virus persistence (overall relative risk,
1.14, 1.01e1.28, I2¼ 44.2%; for oncogenic types relative risk, 1.18, 1.01e1.38, I2¼
0%), and high-grade lesions and cancer (relative risk, 2.01, 1.40e3.01, I2 ¼ 0%), but
women with lesions/cancer were compared with those without, regardless of their
oncogenic human papilloma virus status. Overall, comparable results were found in the
molecular vaginal microbiota studies.
CONCLUSION: This study supports a causal link between vaginal dysbiosis and cervical
cancer along the oncogenic human papillomavirus acquisition, persistence, and cervi-
covaginal dysplasia development pathway.
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dysbiosisMost women across the globe are
infected at least once with 1 ormore HPV
types in their lifetime, but demonstrable
persistence of oncogenicHPV types poses
a direct risk of progression to pre-
malignancy and invasive cervical cancer
in only some individuals.5 This suggests
that other, largely undetermined co-
factors are at play,6 with vaginal dysbiosis
emerging as a potential driver of HPV-
related disease outcomes.6,7
In two meta-analyses of mostly un-
adjusted cross-sectional data, dysbiosisJULY 2019was associated with prevalent HPV
infection and prevalent CIN.8,9 The
latter studies did not allow for causal
inferences while also prone to con-
founding because vaginal dysbiosis and
HPV infection share a number of risk
factors, including sexual behavior and
smoking.6
We postulate that vaginal dysbiosis is a
putative, potentially modiﬁable10 risk
factor to HPV acquisition, persistence,
and related cervical disease and have
systematically reviewed the availableAmerican Journal of Obstetrics& Gynecology 9
AJOG at a Glance
Why was this study conducted?
We conducted this systematic review andmeta-analysis to assess whether vaginal
dysbiosis affects the risk of becoming infected with HPV, clearning HPV, and
developing cervical dysplasia.
Key ﬁndings
Vaginal dysbiosis seems to be a risk factor for acquiring HPV and persistence of
HPV and cervical dysplasia.
What does this add to what is known?
This study is the ﬁrst to pool evidence from longitudinal studies only, while
previous systematic reviews were based on cross-sectional data only. We also
included all diagnostic techniques to assess the vaginal microbiome (microscopy/
molecular).
Systematic Reviews ajog.orgevidence obtained through relevant
longitudinal studies.
Materials and Methods
Eligibility criteria, information
sources, and search strategy
We conducted a systematic literature
review and meta-analysis according to
the Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses
statement11 and searched MEDLINE
(1966 onward), EMBASE (1946 on-
ward), CINAHL (1997 onward),
Cochrane Database (1999 onward), and
Web of Science (1955 onward), without
limits or language restriction, up to June
11, 2018.
The Boolean search string used in
Web of Science, was microbiome or
microbiota or ﬂora or microﬂora or
vaginitis or vaginosis or dysbiosis or
dysbacteriosis and vaginal or vagina or
cervix or cervical or cervicovaginal or
female or women or woman and alpha-
papillomavirus or HPV or human
papillomavirus or uterine cervical neo-
plasms or cancer or dysplasia or
neoplasia or squamous intraepithelial
lesions or low-grade squamous intra-
epithelial lesion (LSIL) or high-grade
squamous intraepithelial lesion (HSIL)
or CIN.
Full search strings for all databases are
detailed in Appendix 1. Only full original
manuscripts were included, but relevant
conference abstracts were cross-checked
for corresponding full-text papers. For
each eligible study, we cross-checked
cited references as well as citing10 American Journal of Obstetrics& Gynecologyreferences in Web of Science. Initial
eligibility screening of all records
retrieved was performed in triplicate (by
H.V., S.S., and N.B.), and no conﬂicts
arose.
Study selection
As described based on the Population,
Intervention/Exposure, Comparison,
Outcome, and Study Design design, we
included original studies with longitu-
dinal cohort designs as well as nested
case-control studies (Study Design) that
compared women (Population) with or
without vaginal dysbiosis (Exposure and
Comparison) and assessed the risk of at
least 1 of the following outcomes
(Outcome): (1) HPV incidence (deﬁned
as detection of an HPV type, not previ-
ously identiﬁed in a given woman) and/
or (2) HPV persistence (deﬁned as an
absence of clearance or signiﬁcantly
delayed clearance relative to a reference
group), and/or (3) related squamous
epithelial lesions, provided vaginal dys-
biosis was considered as a risk factor by
study design. Studies were eligible if at
least 2 measurement points were
described for at least 1 outcome of in-
terest (a minimal time interval was not
predeﬁned).
Vaginal dysbiosis was broadly deﬁned
as deviation from a Lactobacillus-domi-
nated microbiota12 as assessed by mi-
croscopy or molecular techniques,
speciﬁcally 16 rRNA gene or cpn60 gene
sequencing. Preferably, microscopy-
based assessment of dysbiosis (generally
denoted bacterial vaginosis) relied onJULY 2019Gram stainebased methods,13,14 but the
Amsel criteria15 and Papanicolaou’s
smear-based diagnosis16,17 were also
included.
Assessment through vaginal pH mea-
surement alone was not sufﬁcient for
inclusion. Studies that applied molecular
techniques were expected to generate a
variable number of clusters through
compositional dissimilarity approaches
based on taxonomy-speciﬁc relative
abundances,12 with low-Lactobacillus
abundance states to be categorized as
dysbiosis, unless otherwise speciﬁed.
Cytology grading of cervical lesions
was eligible when relying on the
Bethesda System (including the cate-
gories LSIL and HSIL), but the compa-
rable Dutch KOPAC grading system was
also allowed, as previously speciﬁed.8,9
Histology assessment on biopsy or sur-
gical specimens was expected to follow
the CIN histology system (dysplasia
incrementally graded as CIN1, 2, and 3,
respectively). The study protocol has
been registered with the International
Prospective Register of Systematic Re-
views (http://www.crd.york.ac.uk/
prospero) under reference
CRD42016035620.
Data extraction and assessment of risk
of bias
A standardized, pilot-tested form was
used to extract data from possibly
eligible studies for assessment of risk of
bias and for evidence synthesis. All
studies were independently assessed in
triplicate (by H.V., J.v.d.W., and N.B.)
through a customized component
approach addressing a series of meth-
odological hallmarks particular to the
associations for which evidence was
sought (Appendix 2). Speciﬁcally, a nu-
merical score was assigned for selected
study characteristics up to a total of 8
points to each study and subsequently
categorized high (0e3 points), moderate
(4e5 points), and low (6e8 points) risk
of bias. No conﬂicts arose for quality
assessment through this approach.
Data synthesis
Random-effect meta-analyses were per-
formed with STATA (StataCorp LLC,
version 14.2/MP4, College Station, TX)
FIGURE 1
Overview of the systematic literature selection (PRISMA flowchart)
Additional records identified 
through other sources
(n = 0)
Records after duplicates (n=646) removed
(n = 1,645)
Records screened on title
(n = 1,645)
Records excluded on title 
(n=1,437)
(Animal studies n=73, irrelevant 
not English n=207, on cancer 
yet irrelevant n=181, no 
original data, case reports or 
irrelevant abstracts n=181, not 
on association between 
bacterial vaginosis and HPV 
n=795)
Records screened on 
abstract (n =208)
Articles excluded on abstract 
level, with reasons (n =160)
(no original data or abstracts 
n=20, cross-sectional n=110, 
not English, all cross-sectional 
n=9, not on association 
between bacterial vaginosis 
and HPV n=21)
Studies included in 
quantitative synthesis 
(meta-analysis)
(n = 14)
Full-text articles assessed 
for eligibility
(n =48)
Full-text articles excluded, with 
reasons
(n = 33)
(not longitudinal n=23, no data 
on HPV n=1, not on association 
between bacterial vaginosis 
and HPV n=2, on role of 
bacterial vaginosis in 
regression of cervix cancer 
n=4, conference abstracts n=3)
Records identified through 
database searching
(PubMed n=933, Web of Science  
n=1043, Embase n=249, Cinahl 
N=66; Total n=2291)
Studies included in 
qualitative synthesis
(n = 15)
PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
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each outcome and to visualize the results
by means of forest plots. Relative risk
(RR) was used to denote all extracted or
calculated ratio measures of effect and
was pooled and presented with 95%
conﬁdence intervals (CI). These ratios
included odds ratios, risk ratios, rate
ratios (or incidence density ratios, tran-
sition rate ratios), and hazard ratios, and
all were considered to approximate the
same relative risk. If different crude and
adjusted estimates were reported in a
study, the model adjusted for the largest
number of confounders was selected.
Because odds ratios may seemingly
overestimate the effect if the outcome is
prevalent (>10%), risk ratios were
preferred if reported or if crude numbers
were available for assessing incident and
persistent HPV. Transformation of odds
ratios into risk ratios was considered if
this was not reported18,19 by using the
following formula: risk ratio ¼ odds
ratio/[(1 e p) þ (odds ratio*p)], with p
being the proportion of the unexposed
developing the outcome.18 If insufﬁcient
data were available for this trans-
formation, the odds ratio was used.
Subgroup analyses by effect measure,
type of analyses and different deﬁnitions
of exposure, outcomes, and sub-
populations were performed if reported
in 2 or more studies. Statistical hetero-
geneity was assessed by means of
Cochran’s Q and I2 tests, which represent
the percentage of variation attributable
to heterogeneity, and was categorized as
low (25e50%), moderate (51e75%), or
high (>75%).20 The presence of small
study effects or publication bias was not
evaluated because of the low number of
eligible studies.21
Results
Study selection
Fifteen cohort studies published in En-
glish between 2003 and 2017 met the
inclusion criteria (Figure 1),22e36 of
which all but one (with insufﬁcient
data)30 were included in the meta-
analyses.
Study characteristics
Study characteristics of all 15 eligible
studies are summarized in detail inAppendix 3. Most studies originated
from the United States (n ¼
7)22,28,30,31,33,34,36 and Europe (n ¼
5),24,25,27,29,32 with 2 studies potentially
overlapping.33,36
Recruitment age ranged from 13 to 73
years, with 8 studies including post-
menopausal women,22e26,28,35,36 with
mean age ranging between 19 and 39JULY 2019 Ayears (reported in 9
studies22,24,26,27,29e33) and median age
between 16 and 50 years (reported in 4
studies23,25,34,36). Ethnic diversity within
cohorts ranged from 100% white24 to
100% black African/Caribbean/Afro-
American.33,35
Six studies relied on only 2 measure-
ment points,23e26,32,35 while the other 9merican Journal of Obstetrics& Gynecology 11
Systematic Reviews ajog.orgstudies were based on repeated assess-
ment, with a maximum of 32 measure-
ments per woman.22 Sampling intervals
ranged from twice weekly to an average
of 4 years, but typically 4e6 month in-
tervals were handled in 8 studies. Four
studies excluded women with sexually
transmitted infections (STIs) other than
HPV from the study or analyses,25,32,33,35
and another 3 studies adjusted for the
presence of these other STIs.31,34,36
Risk of bias of included studies
Risk of bias was considered high in 6
studies (Appendix 4).24e26,30,32,35
Vaginal dysbiosis was deﬁned by micro-
scopy in 11 studies,23,25e32,34,36 by mo-
lecular techniques in 3 studies, and by
both approaches in 1 study.35 However,
the reported molecular data of the latter
study were insufﬁciently detailed to be
included in our meta-analyses.
Microscopy-based assessment con-
sisted of Nugent scoring in 5
studies,28,32,34e36 wet mount micro-
scopy in 2 studies,30,31 and cervical
Papanicolaou-stained smears in 5
studies.23,25e27,29 The baseline preva-
lence of vaginal dysbiosis ranged from
3% to 54%. All 3 molecular studies
included in themeta-analyses designated
Lactobacillus crispatus dominance as the
reference group.22,24,33
Polymerase chain reaction techniques
were used to identify HPV types as sum-
marized in the Table. HPV involvement
was not assessed in the 3 studies that had
dysplasia or cancer as the outcome.23,25,29
All but 1 of the 12 other studies speciﬁed
the HPV types screened for,26 ranging
between 13 and 49 different HPV types.
Only 3 studies reported results for high-
risk HPV types only.26,32,34
Synthesis of results
Seven studies reported on the association
between vaginal dysbiosis and incident
HPV,22,28,30e33,36, including 2 molecular
studies.22,33 One study did not provide
sufﬁciently detailed numerical data on
incident HPV to be included in the
meta-analysis.30 In the 4 microscopy
studies (Figure 2), the overall risk of
incident HPV was higher among women
with vaginal dysbiosis (pooled RR, 1.35;
95% CI, 1.18e1.50; n ¼ 4), and this12 American Journal of Obstetrics& Gynecologytended to be most prominent among
youngwomen (pooled RR, 1.43; 95%CI,
1.10e1.85; n ¼ 2) (Table).
In the 2 molecular studies, using L
crispatusedominated vaginalmicrobiota
as reference, the risk of incident HPV
was higher when not dominated by L
crispatus (RR, 1.85; 95% CI, 0.47e7.32)
(Table). Only 1 study reported sufﬁ-
ciently detailed information on different
groups not dominated by L crispatus
incident HPV,22 so no meta-analysis
could be conducted. Statistical hetero-
geneity was low among microscopy
studies (I2 ¼ 0%) and moderate across
the molecular studies (I2 ¼ 56).
Nine studies examined the association
between vaginal dysbiosis and HPV
persistence,22,24,26e28,32,34e36 including
2 molecular studies (Figure 3 and
Table).22,24 The 7 microscopy studies
showed a pooled RR of 1.14 (95% CI,
1.01e1.28; n ¼ 7) in women with
vaginal dysbiosis. The risk was most
apparent among asymptomatic women
(RR, 1.86; 95% CI 1.05e3.28; n ¼ 2)
(Table). When only high-risk HPV types
were accounted for, the pooled RR was
1.18 (95% CI, 1.01e1.38; n ¼ 3),
compared with an RR of 1.15 (95% CI,
0.96e1.37; n ¼ 4) for all HPV types
together. The statistical heterogeneity
was low to moderate in all analyses.
In both molecular studies (with L
crispatus dominance as the reference
group), the pooled risk was highest for
anaerobic dysbiosis (RR, 2.00; 95% CI,
1.05e3.81) and lowest for Lactobacillus
gasseri dominance (RR, 0.63; 95% CI,
0.10e3.86).
Three microscopy studies reported on
the association between vaginal dysbiosis
and HPV-related cervical cytological or
histological changes.23,25,29 The large
Dutch screening study provided 3 esti-
mates comparing the risk of atypical
squamous cells of undetermined origin
(ASCUS), LSIL, and HSIL with the
normal cytology category. All 3 estimates
showed a signiﬁcantly increased risk for
womenwithvaginal dysbiosis, correlating
with the degree of dysplasia from 1.44 for
ASCUS, 1.85 for LSIL, and 2.00 for HSIL
(pooled RR, 1.63; 95% CI, 1.32e2.01).25
The other 2 studies enrolled HIV-
positive women only. One studyJULY 2019compared the risk of HSIL or squamous
cell carcinoma (SCC) with a combined
reference group (including normal,
ASCUS, and LSIL categories).29 The
other study provided 2 different risk es-
timates for disease progression from
normal to LSIL to HSIL/SCC in which
ASCUS was added either to the normal
or to the LSIL category.23 The results for
the subgroups based on the reference
and categorization of ASCUS (as
described in the previous text) are pre-
sented separately (Figure 4).
All effect estimates showed a trend
toward an increased risk of disease pro-
gression associated with vaginal dysbio-
sis (except for the analyses in which
ASCUS was grouped with LSIL), but
none of them reached statistical signiﬁ-
cance.23 The 2 studies that assessed the
risk of HSIL/SCC compared with
normal (including ASCUS/LSIL in 1
study) showed a doubled risk among
women with vaginal dysbiosis (pooled
RR, 2.01; 95% CI, 1.40e3.01) and low
heterogeneity (I2 ¼ 0%) (Table).25,29
Comment
Ourmeta-analyses provide evidence that
sexually active women with vaginal dys-
biosis are as follows: (1) at increased risk
of acquiring HPV infection, (2) more
prone to HPV persistence, and/or (3) at
increased risk of progression to associ-
ated premalignant and malignant cervi-
cal disease.
These ﬁndings are consistent with
previous systematic reviews and meta-
analyses based on cross-sectional
data.7e9,12 However, our study is the
ﬁrst to address this research topic through
a systematic appraisal of longitudinal
studies exclusively, retrieved through a
comprehensive literature search of 5
major databases, complemented by
backward and forward citation tracking.
The longitudinal study designs were
such that it was possible to identify
incident and persistent HPV infections
as opposed to just prevalent infections.
However, in all relevant studies that we
identiﬁed, women with (pre)malignant
cervical disease were compared with
those without such disease, regardless of
their oncogenic HPV status. It was
therefore not possible to determine
TABLE
Vaginal dysbiosis and the risk of HPV incidence, persistence, and cervical cancer
Variables Included studies
Number of
included
individuals
Pooled relative
risk (95% confidence
interval) I2, % P heterogeneity
Microscopy studies, incident HPV
Overall 28, 31, 32, 36 5280 1.33 (1.18e1.50) 0.0 .627
Young women 31, 32 1915 1.43 (1.10e1.85) 0.0 .473
HIV positive/high-risk HIV negative 28, 36 4501 1.31 (1.14e1.49) 0.0 .354
Adjusted estimates only 28, 31, 36 4490 1.33 (1.17e1.51) 0.0 .419
Adjusted hazard ratios only 31, 36 3354 1.45 (1.20e1.74) 0.0 .584
Nugent diagnosis 31, 32, 36 4155 1.31 (1.16e-1.48) 0.0 .650
Low- and high-risk HPV combined 28, 31, 36 4490 1.33 (1.17e1.51) 0.0 .419
Molecular studies, incident HPV
Not L crispatus dominated
vs L crispatus dominated
22, 33 96 1.85 (0.47e7.32) 55.7 .133
Microscopy studies, persistent HPV
Overall 26-28, 32, 34-36 4711 1.14 (1.01e1.28) 44.2 .096
Young women 27, 32, 34 618 1.30 (0.77e2.20) 50.0 .136
HIV positive/high-risk HIV negative 28, 35, 36 3386 1.08 (0.97e1.20) 35.4 .212
HIV, high risk 28, 35 401 1.27 (0.57e2.82) 64.9 .058
Adjusted estimates only 28, 34 1287 1.19 (1.03e1.38) 0.0 .942
Hazard ratios only 28, 36 3365 1.09 (0.95e1.25) 67.7 .078
Risk ratios only 26, 27, 32, 34, 35 1017 1.18 (1.01e1.37) 0.0 .789
Nugent diagnosis 28, 32, 34-36 3675 1.05 (1.00e1.11) 0.0 .418
Papanicolaou smear diagnosis 26, 27 1036 1.47 (0.85e2.55) 66.4 .085
Only asymptomatic women 27, 35 350 1.86 (1.05e3.28) 0.0 .328
Including symptomatic women 26, 28, 32, 34, 36 4361 1.10 (1.00e1.21) 35.1 .187
Only high-risk HPV types 26, 32, 34 996 1.18 (1.01e1.38) 0.0 .599
Low- and high-risk types combined 27, 28, 35, 36 3715 1.15 (0.96e1.37) 61.8 .049
Molecular studies, persistent HPV
Not L crispatus dominated
vs L crispatus dominated
22, 24 87 1.33 (0.63e2.81) 23.8 .252
L gasseri dominated vs L crispatus dominated 22, 24 26 0.63 (0.10e3.86) 81.0 .022
L iners dominated vs L crispatus dominated 22, 24 46 1.06 (0.42e2.63) 0.0 .461
Low lactobacilli mixed
aerobe/anaerobe vs L crispatus dominated
22, 24 44 1.00 (0.23e4.30) 80.1 .025
Low lactobacilli anaerobe
vs L crispatus dominated
22, 24 69 2.00 (1.05e3.81) 0.0 .391
Dysplasia/cancer
HSIL vs normal 25, 29 91,149 2.01 (1.40e3.01) 0.0 .768
HIV, human immunodeficiency virus; HPV, human papillomavirus; HSIL, high-grade squamous intraepithelial lesion.
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FIGURE 2
Vaginal dysbiosis and incident HPV
Forest plot showing the association between vaginal dysbiosis and the pooled relative risk of incident HPV using no vaginal dysbiosis as reference.
HPV, human papillomavirus.
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Systematic Reviews ajog.orgwhether vaginal dysbiosis increased
acquisition and persistence of oncogenic
HPV infection only or also increased risk
of carcinogenesis after infection.
The associations that we identiﬁed
may be confounded by the presence of
common risk factors to vaginal dysbiosis
and HPV. Most studies enrolled at-risk
groups for HPV acquisition (ie, young,
sexually active women and women with
high-risk sexual behavior), which inevi-
tably led to marked convergence of
interrelated risk factors and hence to a
high risk of confounding.
The extent to which the studies
adjusted for confounding was highly
variable. For example, only half of the
studies considered the presence of other
STIs or urogenital infections by exclu-
sion at enrollment or through statistical
model adjustment, and very few studies
controlled for all potentially concomi-
tant urogenital infections. For example,
only 1 study reported to have accounted14 American Journal of Obstetrics& Gynecologyfor (culture-positive) vaginal Candida.28
When urogenital infections were taken
into account, this was often done
imperfectly by relying on self-report of
symptomatic vaginal infections by using
insensitive screening assays (for
example, culture for Trichomonas vagi-
nalis instead of culture or a polymerase
chain reactionebased test) or by not
repeating assessments after baseline.
Similarly, little information was pro-
vided on how treatment, if any, of
vaginal dysbiosis, Candida, STIs, and
HPV-related lesions affected outcome.
While confounding requires due atten-
tion, we also observed little difference in
the subanalyses restricted to adjusted
estimates compared with the overall risk
estimates. In addition, several associa-
tions tended to be rather consistent
across different study populations.
However, caution is warranted in
interpreting our pooled risk estimates
because we detected several potentialJULY 2019sources of bias throughout the relevant
literature base. The eligible studies were
implemented in diverse study settings
and included a wide variety of women in
terms of age, socioeconomic status,
ethnicity, past or current sexual risk be-
haviors, and coinfections, whichwas also
reﬂected in the wide-ranging prevalence
of vaginal dysbiosis. Notably, 5 of the 15
eligible studies included a high propor-
tion of HIV-positive women.23,28,29,33,36
Statistical heterogeneity in our analyses
was nonetheless very low to moderate.
Of further concern were differences in
exposure and outcome assessments. The
number of visits, duration of follow-up,
and length of intervals between measure-
ment points varied considerably across
studies. Fluctuations invaginalmicrobiota
status,37e39 as well as in HPV detect-
ability,40,41 may lead to misclassiﬁcation
bias in studies that had few and/or large
intervals between measurement points.
There was also considerable variability in
FIGURE 3
Vaginal dysbiosis and persistent HPV
Forest plot showing the association between vaginal dysbiosis and the pooled relative risk of persistent HPV using no vaginal dysbiosis as reference.
HPV, human papillomavirus.
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Metagenomic analysis recently revealed
the complexity of the HPV virome, which
is only partially visiblewith commonHPV
detection methods,42 with more than half
of HPV-positive women showing coin-
fection with 2 or 3 HPV types.
Co-occurrence patterns speciﬁcally
revealed that colonization with a single,
even low-riskHPV typemay predispose to
additional high-risk HPV types. It is also
known that coinfectionwithmultipleHPV
types is a risk factor for acquiring addi-
tional types and for HPV persistence.43,44
Only 3 of the eligible studies reported an-
alyses conﬁned to high-risk HPV types, so
it may be that our main associations are
diluted by inclusion of HPV types with a
low carcinogenic potential.
Misclassiﬁcation bias relating to
exposure assessment may have been an
evenmore pertinent threat to the validityof some studies. Gram stain Nugent
scoring, which was applied in 5 studies,
has been the gold standard of micro-
scopicmicrobiota assessment in research
settings.13,14 The Amsel criteria (2
studies) are a valid diagnostic approach
but have low sensitivity as a screening
tool in asymptomatic women.15,45
In the HPV and cervical cancer
research ﬁeld, vaginal dysbiosis is often
diagnosed when clue cells are seen on
Papanicolaou smears (5 studies), and the
reported accuracy of this approach is
inconsistent.16,17,46,47 However, overall,
the associations between vaginal dys-
biosis and HPV/cancer were in the same
direction and of a similar magnitude for
studies that assessed the vaginal micro-
biota by molecular methods and those
that used molecular techniques.
While we clearly show associations be-
tween vaginal dysbiosis and HPVJULY 2019 Ainfection, it is remarkable that only a few
HPV epidemiology studies have accoun-
ted for this prevalent risk factor. Different
sexually transmitted pathogens use
different infection strategies, but vaginal
dysbiosis has been shown to be a risk
factor formost STIs,48 as was documented
most extensively for HIV.49 However,
contrary to HIV-1 virions that can pene-
trate both intact squamous and columnar
epithelial barriers,50 HPV capsids are not
able to bind or infect intact epithelia. They
possibly take advantage of the mucosal
barrier failure that has been observed with
vaginal dysbiosis.51
In addition, dysbiosis of mucosa-
associated microbiota is increasingly
recognized as a driver of cancer devel-
opment in humans through a variety of
mechanisms including mucosal barrier
failure and inﬂammation.51,52 Chronic
mucosal inﬂammation is also consideredmerican Journal of Obstetrics& Gynecology 15
FIGURE 4
Vaginal dysbiosis and progression to dysplasia and CIN
Forest plot showing the association between vaginal dysbiosis and the relative risk of progression of dysplasia into cervical intraepithelial neoplasia using
no vaginal dysbiosis as reference.
CIN, cervical intraepithelial neoplasia.
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Systematic Reviews ajog.orgcentral to HPV-induced carcinogen-
esis.53 At least hypothetically, this may
concur with the numerous molecular
signatures of mucosal inﬂammation and
barrier failure with vaginal dysbiosis.54
Of note, recent in vitro data do point to
a protective, antitumoral effect exerted
by vaginal lactobacilli on the cervical
epithelium.55e57
Reverse causation should be consid-
ered because HPVmay also promote the
development of vaginal dysbiosis. HPV
displays a number of immune evasion
and silencing mechanisms, and subtle
changes in the mucosal microenviron-
ment may lead to alterations in the
vaginal microbiota.58 Thus, it cannot be
excluded that such dynamics are at play
in the presence of HPVand/or associated
squamous lesions.
Nonetheless, our data, based on lon-
gitudinal measurements, support the16 American Journal of Obstetrics& Gynecologyhypothesis that the vaginal microbiota
have a role in the pathway from HPV to
cervical cancer at 1 or more disease
stages. As such, our data support the
hypothesis that interventions that
restore and maintain Lactobacillus
dominated vaginal microbiota might
reduce the HPV-related disease
burden,56,57,59e61 thereby possibly
reducing obstetric morbidity related to
excisional and ablative procedures.62
Further prospective studies of vaginal
dysbiosis as a cofactor of HPV-related
disease would be valuable but should
assess vaginal dysbiosis and HPV infec-
tion in more detail using molecular
methods and more frequently over time
and should compare women who have
developed cervicovaginal (pre)malig-
nancy with those without (pre)malig-
nancy but with persistent oncogenic
HPV infection. Such studies mightJULY 2019clarify the role of vaginal dysbiosis in the
different steps in the causal pathway and
may also elucidate several previously
unexplained observations.
Ethnic disparity in cervical cancer
burden has been attributed to increased
HPV persistence in young African-
American women relative to European-
American women.63 However, vaginal
microbiota differences between women
of African or European descent might
also explain this disparity.64
Similarly, the disproportionately high
HPV prevalence among young African
women65 might be directly related to the
high prevalence of vaginal dysbiosis in
sub-Saharan Africa.66 The vulnerability
of sexually active adolescents toHPValso
warrants further scrutiny, speciﬁcally as
it may relate to the putative association
between cervical ectopy and vaginal
dysbiosis67 and to the role of the
ajog.org Systematic Reviewsadolescent vaginal microbiota in
mucosal immune homeostasis.68,69
In conclusion, vaginal dysbiosis likely
is a largely understudied yet important
risk factor in HPV and cervical cancer
epidemiology. Improved HPV vaccina-
tion coverage and vaginal dysbiosis pre-
vention and management will likely
reduce cervical cancer disease burden
signiﬁcantly. Expanding the evidence
base may also lead to novel primary and
secondary preventive strategies. -
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Detailed search strategy
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CIN, cervical intraepithelial neoplasia; HPV, human papillomaviru
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APPENDIX 2
Quality assessment composite grading tool
Quality criteria Total points
The inception study had a prospective cohort design (including nested case-control
study)
1
The study sample was representative for the population specified, not necessarily
the community or background population
1
Assessment of vaginal dysbiosis was pursued through Gram-stainedebased
microscopy or a microbiome-wide sequencing approach
1
The study was adequately powered relative to the incidence of dysbiosis, HPV
infection and related laesions
1
Potential confounders (including the major confounders smoking, parity, hormonal
contraception, HIV, and concomitant STIs) were properly assessed and accounted for
in the analysis
0.5 if several, although not all major confounders were
accounted for and 1 point for comprehensive control
The analysis was based on repeated, serial assessment of vaginal microbiota status
and incident HPV and/or related laesions (in contrast to a single follow-up visit)
1
Intermittent treatment of vaginal dysbiosis and of CIN was reported and/or accounted
for in the analysis
0.5 for each and hence 1 point for both
Loss to follow-up was not likely to impinge on results (1 point) 1
Brusselaers. Bacterial vaginosis, HPV, and cervical cancer. Am J Obstet Gynecol 2019.
A total of 8 points can be assigned to each study, categorized as:
1e3: high risk of bias (low-quality evidence)
4e5: moderate risk of bias (moderate-quality evidence)
6e8: low risk of bias (high-quality evidence)
CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus; STI, sexually transmitted infection.
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APPENDIX 3
Study characteristics of all 15 studies included in the systematic review
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AIDS, acquired immunodeficiency syndrome; ASCUS, atypical squqmous cells of undetermined origin; CIN, cervical intraepithelial neoplasia; CST, community state type; HPV, human papilloma virus;
HSIL, high-grade squamous intraepithelial lesions; KOPAC, Dutch alternative classification of cytological changes in cervical smears; LEEP, loop electrosurical excision procedure; LSIL, low-grade
squamous intreaepithelial lesions; n.a., not applicable; n.r., not reported; Pap smear, Papanicolaou test; PCR, polymerase chain reaction; RNA, ribonucleic acid; SIL, squamous intreaepithelial le-
sions; STI, sexually transmitted infection; UK, United Kingdom; USA, United States of America.
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APPENDIX 4
Quality assessment of all 15 eligible studies included in the qualitative analyses
Mao
et al
Samoff
et al
Watts
et al
Engberts
et al
Lehtovirta
et al
Moscicki
et al
Denslow
et al
King
et al
Guo
et al
Oakeshott
et al
Brotman
et al
Reimers
et al
Di Paola
et al
Kero
et al
Shannon
et al
200330 200534 200536 200725 200829 201031 201123 201128 201226 201232 201422 201633 201724 201727 201735
Indicator
Prospective þ þ þ e e þ þ þ e þ þ þ þ þ þ
Representative
sample
e - þ þ þ þ þ þ þ e e þ e þ e
Gram stain or PCR e þ þ e e e e þ e þ þ þ þ þ þ
Adequately
powered
e e þ þ þ þ e þ þ e e e e þ e
Control for
confounders
 e  e  þ  þ e þ e  e e e
Serial assessment þ þ þ e þ þ e þ e e þ þ e þ e
Intermittent
treatment
   e  e   e e   e e e
Loss to follow-up e e þ þ þ þ þ þ þ e e þ þ e þ
Quality score
(numerical)
3/8 4/8 7/8 3/8 5/8 6/8 4/8 7.5/8 3/8 3/8 3.5/8 6/8 3/8 5/8 3/8
Risk of bias
(categorical)
High Moderate Low High Moderate Low Moderate Low High High Moderate Low High Moderate High
PCR, polymerase chain reaction.
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APPENDIX 5
Articles excluded with reasons, based on full text assessment
In total 33 studies were excluded after screening of the full text.
- Not longitudinal or the necessary data were incomplete, n ¼ 23.1e22
- No data on HPV, n ¼ 1.23
- Not on the association between bacterial vaginosis and HPV, n ¼ 2.24,25
- On role of bacterial vaginosis in regression/progression of cervical cancer, n ¼ 4.26e29
- Conference abstracts, n ¼ 3.30e32
Brusselaers. Bacterial vaginosis, HPV, and cervical cancer. Am J Obstet Gynecol 2019.
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